These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19887136)

  • 1. Systemic, nasal and oral live vaccines against Pseudomonas aeruginosa: a clinical trial of immunogenicity in lower airways of human volunteers.
    Bumann D; Behre C; Behre K; Herz S; Gewecke B; Gessner JE; von Specht BU; Baumann U
    Vaccine; 2010 Jan; 28(3):707-13. PubMed ID: 19887136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment of pulmonary antibodies with induced sputum and bronchoalveolar lavage induced by nasal vaccination against Pseudomonas aeruginosa: a clinical phase I/II study.
    Baumann U; Göcke K; Gewecke B; Freihorst J; von Specht BU
    Respir Res; 2007 Aug; 8(1):57. PubMed ID: 17683588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune responses in the airways by nasal vaccination with systemic boosting against Pseudomonas aeruginosa in chronic lung disease.
    Sorichter S; Baumann U; Baumgart A; Walterspacher S; von Specht BU
    Vaccine; 2009 May; 27(21):2755-9. PubMed ID: 19366571
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced immunogenicity in the murine airway mucosa with an attenuated Salmonella live vaccine expressing OprF-OprI from Pseudomonas aeruginosa.
    Arnold H; Bumann D; Felies M; Gewecke B; Sörensen M; Gessner JE; Freihorst J; von Specht BU; Baumann U
    Infect Immun; 2004 Nov; 72(11):6546-53. PubMed ID: 15501786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salmonella Typhimurium strain expressing OprF-OprI protects mice against fatal infection by Pseudomonas aeruginosa.
    Zhang M; Sun C; Gu J; Yan X; Wang B; Cui Z; Sun X; Tong C; Feng X; Lei L; Han W
    Microbiol Immunol; 2015 Sep; 59(9):533-44. PubMed ID: 26249788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunization of young African green monkeys with OprF epitope 8-OprI-type A- and B-flagellin fusion proteins promotes the production of protective antibodies against nonmucoid Pseudomonas aeruginosa.
    Weimer ET; Ervin SE; Wozniak DJ; Mizel SB
    Vaccine; 2009 Nov; 27(48):6762-9. PubMed ID: 19744586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa.
    Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM
    J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.
    Westritschnig K; Hochreiter R; Wallner G; Firbas C; Schwameis M; Jilma B
    Hum Vaccin Immunother; 2014; 10(1):170-83. PubMed ID: 24064511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mannose-modified chitosan microspheres enhance OprF-OprI-mediated protection of mice against Pseudomonas aeruginosa infection via induction of mucosal immunity.
    Cui Z; Han D; Sun X; Zhang M; Feng X; Sun C; Gu J; Tong C; Lei L; Han W
    Appl Microbiol Biotechnol; 2015 Jan; 99(2):667-80. PubMed ID: 25381907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccines and immunotherapy against Pseudomonas aeruginosa.
    Döring G; Pier GB
    Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recombinant OprF-OprI as a vaccine against Pseudomonas aeruginosa infections.
    Baumann U; Mansouri E; von Specht BU
    Vaccine; 2004 Feb; 22(7):840-7. PubMed ID: 15040936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mucosal vaccination with a recombinant OprF-I vaccine of Pseudomonas aeruginosa in healthy volunteers: comparison of a systemic vs. a mucosal booster schedule.
    Göcke K; Baumann U; Hagemann H; Gabelsberger J; Hahn H; Freihorst J; von Specht BU
    FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):167-71. PubMed ID: 12832121
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outer membrane proteins of Pseudomonas aeruginosa as vaccine candidates.
    von Specht BU; Domdey H; Schödel F; Blum B; Lücking C; Knapp B; Muth G; Hungerer KD; Bröker M
    Behring Inst Mitt; 1994 Dec; (95):85-96. PubMed ID: 7538752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicenter vaccine trial using the Pseudomonas aeruginosa flagella vaccine IMMUNO in patients with cystic fibrosis.
    Döring G; Dorner F
    Behring Inst Mitt; 1997 Feb; (98):338-44. PubMed ID: 9382758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experimental immunization with Pseudomonas aeruginosa alginate induces IgA and IgG antibody responses.
    Johansen HK; Høiby N; Pedersen SS
    APMIS; 1991 Dec; 99(12):1061-8. PubMed ID: 1772641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Local immunization against P. aeruginosa with an outer-membrane-protein vaccine].
    Grundmann T; Freihorst J; Kubesch P; Tümmler B; von der Hardt H
    Pneumologie; 1991 Nov; 45(11):924-7. PubMed ID: 1763004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal and systemic antibody responses to potential Pseudomonas aeruginosa vaccine protein antigens in young children with cystic fibrosis following colonization and infection.
    Moore R; Kyd JM; Carzino R; Armstrong D; Grimwood K; Otczyk DC; Cripps AW
    Hum Vaccin Immunother; 2013 Mar; 9(3):506-14. PubMed ID: 23249482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of vaccine technology to prevention of Pseudomonas aeruginosa infections.
    Pier G
    Expert Rev Vaccines; 2005 Oct; 4(5):645-56. PubMed ID: 16221066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.
    Weimer ET; Lu H; Kock ND; Wozniak DJ; Mizel SB
    Infect Immun; 2009 Jun; 77(6):2356-66. PubMed ID: 19349426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilin-based anti-Pseudomonas vaccines: latest developments and perspectives.
    Hahn H; Lane-Bell PM; Glasier LM; Nomellini JF; Bingle WH; Paranchych W; Smit J
    Behring Inst Mitt; 1997 Feb; (98):315-25. PubMed ID: 9382755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.